Visceral leishmaniasis (VL) is a parasitic disease occurring in South Asia, East Africa, South America and the Mediterranean area. It is caused by different species of Leishmania parasites and acquired by the bite of an infected female of one of several species of tiny hairy mosquitoes, called 'sandflies', inoculating the parasites in the bloodstream. VL is an opportunistic infection in HIV patients with CD4 counts below 200 Â 10 6 /l. 1 Patients with an acquired immunodeficiency following organ transplantation may also encounter VL. Recently, Basset et al. 2 reviewed 56 cases of VL in organ transplant recipients (44 kidney, 6 liver, 3 heart, 2 lung, 1 kidney plus pancreas). Only one case with VL after hematopoietic stem cell transplantation (HSCT) has been reported so far. 3 Without anti-leishmanial treatment, VL can be rapidly fatal in transplant recipients. Even despite treatment, the mortality of VL in transplantation patients is high: 10 out of 49 patients (20.4%), as reported by Basset et al., 2 while relapses after specific therapy occurred in 10-20% of patients after 1 month until 5 years.
We recently treated a recipient of an allogeneic HSCT for VL, in whom leishmaniasis was diagnosed accidentally. In January 2000, a 59-year-old man was diagnosed with follicular lymphoma, stage IIIa (neck, mesentery and hilum left kidney) and a low FLIPI score. He was treated with eight courses of CVP therapy (cyclophosphamide 750 mg/ m 2 Â 1 day, vincristine 2 mg Â 1 day, prednisolone 40 mg/ m 2 Â 5 days) and irradiated to a residual mass in the left renal hilum (4 Gy). Evaluation showed a complete response to treatment. In May 2003, a relapse was diagnosed and he was treated with six courses of R-CHOP therapy (rituximab 375 mg/m 2 Â 1 day, cyclophosphamide 750 mg/m 2 Â 1 day, doxorubicin 50 mg/m 2 Â 1 day, vincristine 1.4 mg/ m 2 Â 1 day, prednisolone 100 mg Â 5 days) and rituximab as maintenance therapy. A partial remission was obtained that continued till November 2004, when we started with fludarabine therapy for overt progression. It resulted in a partial remission. In September 2005, the patient received a matched unrelated donor (MUD) transplant after a reduced-intensity conditioning regimen (rabbit-ATG 8 mg/ kg, fludarabine 90 mg/m 2 , TBI 2 Gy). Because of the expected short during leukopenia, we did not prescribe prophylactic fungal therapy like amphotericin B. Complications were atrial fibrillation, diarrhea and an oral infection of herpes simplex type I.
In December 2005, the patient was readmitted to the hospital after detection of a cytomegalovirus (CMV) reactivation with 80 000 genome equivalents (geq) per ml. This CMV load decreased rapidly to o50 geq/ml after 1 week treatment with intravenous ganciclovir and three times administration of CMV immunoglobulin. EpsteinBarr virus (EBV) reactivation was found with a maximal load of 3000 geq/ml, which decreased rapidly after treatment with 375 mg/m 2 rituximab. The bone marrow smear showed no signs of lymphoproliferative disease, but to our surprise numerous amastigotes of Leishmania spp. were seen ( Figure 1 ). Leishmania parasites were also demonstrated in May-Gru¨nwald stained peripheral blood smears ( /l), but the patient had no clinical signs of fever or hepatosplenomegaly. DNA was isolated from blood and bone marrow with QIAamp Blood Kit spin columns using the manufacturer's recommendations. Leishmania-specific PCR primers and a Leishmania-specific Taqman probe were used as described by Wortmann et al. 4 In each sample, 10 3 PFU/ml phocin herpes virus 1 (PhHV-1) was added within the isolation lysis buffer to serve as internal control and was amplified and detected within the same reaction with PhHV-1-specific primers and probe. 5 Species differentiation was performed using PCR-RFLP analysis as described by Minodier et al. 6 Analysis of both bone marrow and peripheral blood samples taken in January 2006 identified the infecting protozoan as Leishmania infantum. However, the direct agglutination assay (DAT) of the blood sample was negative. Sensitivity estimates of the DAT to detect VL are considered high (96.9, 95% confidence interval 94.1-99.8%) and latent class analysis of the estimated specificity of the DAT is 93.7, 95% confidence interval 88.0-99.4%. 7 Therefore, it can be assumed that no significant antibody production occurred. In this case, 100% specificity was reached by demonstrating the parasites submicroscopically and by positive PCR.
The patient was treated with liposomal amphotericin B (Ambisome) 4 mg/kg once per day for 10 days, and thereafter six infusions during a 6-week-period. No Leishmania amastigotes were detectable in bone marrow smears at the end of treatment.
VL can be acquired in three ways, by the already mentioned sandfly bite, by inoculation of parasites by sharing contaminated syringes in intravenous drug users, or by an infected graft. 8 In our case morphological, PCR and serological tests were all negative in donor samples, so it is unlikely that the infection was donor-derived. In patients with acquired immunodeficiency most often recrudescence of a latent infection is suspected.
Retrospective examination of a bone marrow smear from our patient obtained in December, 1 month before the infection was diagnosed, showed sporadic amastigotes. Retrospective analysis by PCR of a peripheral blood sample from that time was positive for Leishmania infantum. However, microscopic examination of blood smears taken 3 and 6 months before HSCT were negative. PCR and serology of EDTA and serum samples of peripheral blood taken 6 and 3 months before and at PBSCT proved all to be negative (Table 1) . These data clearly indicate a de novo infection.
A review of the patient's history revealed travel to the Ce´vennes region in southern France 4 weeks before transplantation. Leishmania infantum is endemic in the Mediterranean area. Since no infection could be detected in samples up to 3 months before HSCT it is suggested that our patient was infected with Leishmania just before admission for HSCT.
Asymptomatic infections do occur in immunocompetent individuals. If VL develops, the incubation period is usually between 2 and 4 months, but can be from 10 days to 2 years. In cutaneous leishmaniasis, specific antibody production cannot be detected. It is assumed that antibodies only develop after dissemination of infection. So as long as the parasites remain in the initial skin lesion at the sandfly bite, no detectable antibody production is to be expected. We can only speculate about the location of the parasites during the short period before the HSCT procedure, but there is no reason to doubt the ability of the patient to develop a proper humoral response in this period.
A severe immunodeficiency characterized by a deep lymphopenia, which is induced by ATG, is a well-known risk factor for opportunistic EBV and CMV infections, but opportunistic parasitic infections have been reported less frequently.
9,10 Halkic et al. 11 suggested that opportunistic CMV infections with a high viral load, as encountered by our patient, may additively trigger leishmaniasis in patients from endemic area's with latent infections. However, VL and CMV reactivation in the present patient can both be caused by the same conditions brought about by the deep lymphopenia.
In the present recipient, all DAT results proved to be negative after HSCT. Negative serological tests more often occur in immunosuppressed recipients of allogeneic stem cell grafts. In immunocompromised patients with and without AIDS fever and hepatosplenomegaly are not always found, but pancytopenia has been the most consistent finding. 12 In conclusion, we report a case of VL as an opportunistic infection following allogeneic HSCT. A history of travel to an endemic region should alert clinicians to the possibility of opportunistic Leishmania infections. Because of the serious morbidity and mortality associated with untreated leishmaniasis, we advise screening by serology for leishmaniasis before HSCT or any other transplant surgery as this will detect most infections in patients who live in or visited endemic areas. 12 However, examination of bone marrow smears was the first diagnostic method in 16 of 18 transplant recipients described by Berenguer et al.
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